More than 3 million Americans are diagnosed with some form of Arthritis annually, making it one of the most common health issues in the United States. Arthritis encompasses over one hundred different forms of joint pain and disease, and while conditions such as osteoarthritis and rheumatoid arthritis are extremely prevalent, they remain misunderstood. Current remedies for arthritis include anti-inflammatories and pain relievers such as steroids, DMARDs, and biologics; however, they often come with undesirable side-effects such as nausea, vomiting, high blood pressure, infection, and vision problems. Exciting preliminary research suggests Cannabidiol (CBD) provides the same anti-inflammatory, pain-relieving effects without any of these adverse consequences.
A 2016 study conducted by the University of Kentucky’s Pharmaceutical Sciences Department revealed preliminary, pre-clinical evidence of a positive relationship between transdermal CBD administration and inflammation and pain caused by arthritis. In the study, a cohort of 54 rats (including 23 adjuvant-induced arthritis subjects) were examined for joint circumference, immune cell invasion, and paw withdrawal latency (PWL) after transdermal (on-skin) administration of 0.6, 3.1, 6.2, and 62.3 mg/day of CBD. Joint circumference and immune cell invasion served as markers of inflammation, while PWL provided information about the rats’ overall pain. Transdermal administration of CBD reduced joint circumference, minimized immune cell infiltration, and returned PWL near baseline levels without any adverse side-effects. Overall, preliminary animal models suggest CBD provides anti-inflammatory, pain-relieving remedies for arthritis without any of the adverse side-effects of prescribed medications.
CBD is a holistic remedy that is carefully grown and manufactured from soil to oils. Its anxiolytic, therapeutic, and now, anti-inflammatory, pain-reducing capabilities could make it the ideal natural supplement to bring relief to arthritis sufferers. The University of Kentucky’s preliminary research on CBD for arthritic pain lays the groundwork for additional research and potentially a pain-free future for many patients.
This article was written by the researchers at Green Rock Hemp Holdings based on the following study: Hammell, D.C., Zhang, L.P., et. al. (2016). Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. European Journal of Pain: July 20(6): 936–948. Department of Pharmaceutical Sciences, University of Kentucky College of Pharmacy, Lexington, KY.
Green Rock Hemp Holdings, LLC (GRHH) is a professional, vertically integrated solutions provider to the industrial hemp community. From seed to CBD, GRHH and its affiliates—GeneticsCubed, LLC; Mesa Rising Hemp Farms, LLC; Red Dune Seed, LLC; Red Mesa Science & Refining, LLC; and Enhanced Botanicals, LLC—provide farmers, consumer goods producers, and end customers with the highest quality products and solutions. From scientific genome, seed development, and mindful cultivation, through state-of-the-art processing and extraction, GRHH brings proven business practices to the emerging hemp industry.